Objective: Despite World Health Organization recommendations, concerns about promoting resistance have impeded implementation of isoniazid preventive therapy (IPT) for tuberculosis (TB). We describe characteristics of TB in individuals previously exposed to IPT as part of 'Thibela TB', a cluster-randomized trial of community-wide IPT in gold miners in South Africa.
Introduction
Despite World Health Organization recommendations [1] and strong evidence of effectiveness [2] [3] [4] , implementation of isoniazid preventive therapy (IPT) to reduce HIV-associated tuberculosis (TB) has been limited. Reasons include concerns about promoting drug resistance, although there is little evidence that this occurs [5] . TB incidence in South Africa was estimated at 948/ 100 000 in 2007 [6] and is higher still among miners, partly due to high prevalence of HIV (estimated at 29%) [7] and silicosis [8] . The prevalence of latent TB infection among gold miners was recently estimated at 89% [9] . We are conducting a cluster-randomized trial ('Thibela TB') of community-wide IPT among gold miners in South Africa. The aim of this analysis was to describe characteristics of TB disease in individuals previously exposed to IPT in this trial.
Methods

Setting
Mining companies provide employees with free, on-site comprehensive healthcare, including TB and HIV services. In the Thibela TB study, clusters (all employees at a single or group of mine shafts) were randomized to control (routine TB control, including annual case finding by chest radiograph and targeted IPT offered to individuals with HIV or silicosis) or intervention (routine TB control as above plus the study intervention, i.e. TB screening and IPT offered to all employees without a specific contraindication, regardless of perceived TB risk or HIV status) arms. In intervention clusters, screening for active TB and other contraindications is by symptom questionnaire and chest radiograph [7, 10, 11] . Eligible participants are dispensed isoniazid 300 mg and pyridoxine 25 mg daily, self-administered, for 30 days initially and 9 months in total, with monthly review by nurses at workplace-based study clinics for TB symptoms and adverse events.
Study population and case ascertainment
Individuals were included in this case series ('TB after IPT' group) if they were dispensed IPT at one of eight intervention clusters (starting July 2006), attended at least one follow-up visit and subsequently started TB treatment (up to 16 February 2009). Cases were identified through surveillance of incident TB as part of Thibela TB, through a concurrent mycobacterial culture substudy and through review of clinical records for individuals stopping IPT early. We included all those treated for TB, who attended at least one follow-up visit (to be reasonably sure that some isoniazid had been taken), unless an outcome of 'not TB' was recorded or only nontuberculous mycobacteria were isolated from sputum.
Definitions
Sites of disease, episode type, treatment regimens and outcomes (standard WHO definitions [12] ) were abstracted from TB treatment records. We estimated the maximum duration of IPT using the number of monthly dispensing visits. Participants stopping IPT before 9 months were assumed to have taken medication for 15/30 days preceding their final visit.
Comparison groups
To provide comparisons for the proportion with drug resistance in the TB after IPT group, we used two data sources:
(1) 'Control clusters': TB case ascertainment in the seven control clusters was identical to that in intervention clusters. All TB cases with available drug susceptibility data from two large control clusters were included in this comparison group. (2) 'Laboratory substudy': sputa from individuals presenting to clinics with symptoms but no prior history of TB underwent culture and drug susceptibility testing [13] . All TB cases in the laboratory substudy at any control cluster were included.
The TB after IPT group included those who had not yet completed treatment in order to avoid excluding those with longer treatment duration; that is retreatment cases or drug-resistant TB. This was not possible in the control cluster comparison group, as laboratory data are not abstracted until the end of treatment. In the laboratory substudy, this was not an issue, as specimens were collected at the time of investigation for TB and thus drug susceptibility data were available in real time. Tuberculosis screening failures in the tuberculosis after isoniazid preventive therapy group Four individuals most likely had TB that was missed at screening before IPT. Two were culture positive with fully susceptible M. tuberculosis from specimens taken due to abnormal chest radiographs, but IPT was dispensed in error: they were started on first-line treatment 9 and 184 days after starting IPT and outcomes were transfer-out and cure, respectively. The individual starting treatment after 184 days had taken an estimated 45 days of IPT and a later sputum specimen grew isoniazid-resistant M. tuberculosis. The other two had negative TB screens at the Thibela TB study site and were smear and culture negative on specimens taken later by mine health services, which initiated treatment based on results of occupational screening radiographs after 11 and 14 days of IPT. Both were documented to have completed treatment.
Statistical methods
Discussion
Concern about generating isoniazid resistance is a major obstacle to wider implementation of IPT. These data do not support this concern. Treatment outcomes were typical of this setting, taking into account the high numbers of transfers to other treatment programmes and unrecorded outcomes. South Africa as a whole has not yet met the WHO targets for treatment outcomes [6] . Drug resistance was not more prevalent than in comparison groups. Among first episodes of TB, the prevalence of isoniazid resistance, at 12.1%, was higher in the TB after IPT group than in control clusters (6.0%), but similar to that in the laboratory substudy (11.8%). In retreatment cases, isoniazid resistance was less common in the TB after IPT group than in control clusters (7.7 vs. 18.7%). The prevalence of isoniazid resistance in the TB after IPT group is also in keeping with a drug-resistance survey among gold miners in this area in the 1990s in which 7.3% (95% CI 6.1-8.7) of first TB episodes and 14.3% (11.3-17.9) of retreatment episodes had isoniazid resistance [14] . In this analysis, we present several comparators, acknowledging that each has limitations. Overall, although numbers of resistant cases were small and CIs accordingly wide, the data do not suggest an increase in proportion of isoniazid-resistant cases among those exposed to TB screening and IPT.
Treatment of latent TB should not, theoretically, promote antituberculous drug resistance, as in latent infection the probability of selecting for a spontaneously-occurring isoniazid-resistant organism is remote, as organism numbers are low and bacterial division slow [15] . In a population of individuals with latent TB exposed to IPT, a higher prevalence of isoniazid resistance among subsequent TB cases would be expected even if IPT use did not itself generate resistance, as IPT is assumed to be more effective in treating isoniazid-susceptible than isoniazid-resistant latent TB.
We reported on TB episodes occurring during or relatively early after completing IPT. Given the high prevalence of HIV and TB in this population, the majority of TB cases are likely to have been due to recent infection [16] . However, this relatively short follow-up inevitably biases toward cases identified during IPT, who are those most likely to have been screening failures, to have received inadvertent monotherapy for active disease, and hence to have acquired isoniazid resistance. With longer follow-up, we would expect an increasing proportion of cases to be due to re-infection after IPT.
The control cluster comparison group may be biased toward a lower proportion with resistance, as drug susceptibility data are collected at the end of the treatment episode, thus potentially excluding individuals with longer treatment durations, due to previous treatment exposure or known baseline resistance. Effective screening before administering IPT is essential to avoid inadvertent isoniazid monotherapy for active TB. Overall consensus on the optimal screening method in resourcelimited settings is yet to be reached.
Three previous papers specifically describe active TB following IPT [17] [18] [19] . Methods differ and numbers are very small, so it is difficult to draw clear conclusions in terms of drug resistance from these studies. Data concerning TB after IPT from clinical trials have been reviewed previously in a meta-analysis [5] . The summary estimate for the risk of isoniazid resistance following IPT compared with those not exposed to IPT was 1.45 (95% CI 0.85-2.47), suggesting no evidence for an increase in resistance.
In conclusion, TB disease among mostly HIV-infected people previously exposed to IPT had treatment outcomes typical of this setting and a similar prevalence of isoniazid resistance to background. Concerns about generating drug resistance should not impede implementation of IPT. Fig. 1 . Percentages of tuberculosis episodes with any isoniazid resistance (bars show 95% confidence intervals).
